Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In predialysis stage 3-5 diabetic and nondiabetic CKD patients, CAVI levels and its relation to atherosclerosis-associated risk factors including monocyte-chemoattractant protein-1 (MCP-1), sclerostin, fibroblast growth factor-23 (FGF-23), Klotho, and 25-OH vitamin D were determined.
|
31773386 |
2020 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CCL2 expression was associated with a significant predictive value of atherosclerosis.
|
31739217 |
2020 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that MCP-1 blocking may be crucial in preventing the endothelial dysfunction induced by contrast medium in patients with inflammatory disease and atherosclerosis.
|
30918133 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition to greater levels of systemic inflammation, heightened monocyte activation (sCD163, CCL2) may contribute to the burden of atherosclerosis among HIV-infected persons.
|
30946765 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Experimental evidence and Mendelian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis and stroke.
|
31476962 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This trial evaluated the potential impacts of saffron aqueous extract (SAE) and its main carotenoid on some of the atherosclerosis-related gene expression and serum levels of oxidized low-density cholesterol (ox-LDL) and Monocyte chemoattractant protein 1 (MCP-1) in patients with coronary artery disease (CAD).
|
31797473 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MCP-1 and FGF-21 levels are associated with subclinical atherosclerosis disease severity (i.e., cIMT) in postmenopausal women without CVD.
|
31152776 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a proinflammatory cytokine that plays a key role in the development of atherosclerosis.
|
31388753 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, CTRP9 downregulated the expressions of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α), two main proinflammatory cytokines in atherosclerosis.
|
30426302 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the specific regulatory mechanism of MCP1 overexpression in AS is still unclear.
|
31737059 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The interaction between monocyte chemoattractant protein-1 and chemokine receptor 2 (CCR2) may be the cause of atherosclerosis, obesity, and insulin resistance.
|
29251559 |
2019 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
During inflammation, meprin functions to regulate chemokine activity of monocyte chemotactic protein 1, which is associated with chronic inflammatory diseases, including atherosclerosis, renal inflammatory diseases, and multiple sclerosis (MS).
|
31203904 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this work, we synthesized monocyte-targeting iron oxide magnetic nanoparticles (MNPs), which were incorporated with the peptides derived from the chemokine receptor C-C chemokine receptor type 2 (CCR2)-binding motif of monocytes chemoattractant protein-1 (MCP-1) as a diagnostic tool for potential atherosclerosis.
|
29795012 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies indicate that chemokine CC-motif ligand 2 (CCL2) is involved in inflammation and atherosclerosis.
|
29864522 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The most promising anti-inflammatory compounds for treatment of atherosclerosis include non-specific anti-inflammatory drugs, phospholipase inhibitors, blockers of major inflammatory cytokines, leukotrienes, adhesion molecules, and pro-inflammatory signaling pathways, such as CCL2-CCR2 axis or p38 MAPK pathway.
|
29378168 |
2018 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Infection with an adenovirus delivering the EMMPRIN-siRNA ameliorated AS, promoted macrophage autophagy in plaques and reduced the serum TNF-α, IL-6, MCP-1 and NF-κB expression levels in the AS mice.
|
29154780 |
2018 |
Atherosclerosis
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, 7,8,4'-THI significantly downregulated TNF-α stimulated the expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and phosphorylation of IκB kinase and IκBα involved in the initiation of atherosclerosis in HUVECs.
|
28946319 |
2018 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Canagliflozin attenuates the progression of atherosclerosis, reducing (1) hyperlipidemia and hyperglycemia, and (2) inflammatory process, by lowering the expression of inflammatory molecules such as MCP-1 and VCAM-1.
|
30049285 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MCP-1 did not correlate with intermediate CV outcomes, implicating pathways other than atherosclerosis in the association of MCP-1 with death in CKD.
|
29874658 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein 1 (MCP1) with recruiting monocytes is an important factor at the beginning of inflammatory disorders such as atherosclerosis which seems its blocking preclude this process and help improvement of related diseases.
|
29596634 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Target specific therapies directed at pro-inflammatory cytokines such as IL-1β, IL-6, TNFα, and CCL2 have demonstrated slowing in the progression of atherosclerosis in animal models and improved cardiovascular outcomes in human subjects.
|
30006321 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, in this study, cPA had no effect on the expression and secretion of C-C motif chemokine 2 (CCL-2), a chemokine that is also linked to inflammatory responses and atherosclerosis.
|
29990859 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the serum MCP-1 concentration is higher in patients with than without cardiovascular disease, the precise correlations between the serum MCP-1 concentration and factors associated with smoking and atherosclerosis are unknown.
|
29098933 |
2018 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, serum MCP-1 and VE-cadherin levels were correlated with atherosclerosis and the stability of atherosclerotic plaques in patients with cerebral infarction.
|
28272702 |
2017 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, ghrelin can inhibit intraplaque angiogenesis and promote plaque stability by down-regulating VEGF and VEGFR2 expression, inhibiting the plaque content of macrophages, and reducing MCP-1 expression at an advanced stage of atherosclerosis in rabbits.
|
28189525 |
2017 |